Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

Acceptability & Impact of a Diabetes Management Smartphone App (mySugr) for Spanish-literate Adults With Type 2 DiabetesCompleted
NCT05975242NAUpdated Dec 5, 2024
Sponsor: Sansum Diabetes Research Institute
Diabetes Mellitus, Type 2
United States
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead InCompleted
NCT02708680Phase 1, Phase 2Updated Dec 4, 2024
Sponsor: Syndax Pharmaceuticals
Breast Cancer
United States, Georgia
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)Unknown
NCT04551495Phase 2Updated Dec 4, 2024
Sponsor: Jules Bordet Institute
Invasive Lobular Breast Carcinoma · ER+ Breast Cancer · HER2-negative Breast Cancer
Belgium, France
De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 BlockadeTerminated
NCT04675827Phase 2Updated Dec 4, 2024
Sponsor: Jules Bordet Institute
HER2-positive Breast Cancer · ER-Negative Breast Cancer · PR-Negative Breast Cancer · Node-negative Breast Cancer
Australia, Belgium, France, Israel, South Korea +1 more
Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144Terminated
NCT02403323Phase 3Updated Dec 2, 2024
Sponsor: Hoffmann-La Roche
Crohn Disease
United States, Argentina, Australia, Austria, Belgium +28 more
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin LymphomaActive Not Recruiting
NCT03671018Phase 1, Phase 2Updated Nov 29, 2024
Sponsor: Hoffmann-La Roche
B-cell Non-Hodgkin Lymphoma
United States, Belgium, Canada, Spain, United Kingdom
ELFI Health (e-Health for Empowerment by Lifestyle, Food Advice and Interaction)Completed
NCT06236334NAUpdated Nov 22, 2024
Sponsor: TNO
Pre-diabetes
Netherlands
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3ACompleted
NCT02406092Phase 3Updated Nov 21, 2024
Sponsor: Hoffmann-La Roche
Non-Hodgkin Lymphoma
Algeria, Morocco, Tunisia
Tiragolumab and Atezolizumab in Advanced Pan-cancer PatientsRecruiting
NCT06003621Phase 2Updated Nov 15, 2024
Sponsor: Omico
Solid Tumor, Adult
Australia
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)Terminated
NCT04933227Phase 2Updated Nov 14, 2024
Sponsor: Hoffmann-La Roche
Stomach Neoplasms · Gastric Cancer · Gastroesophageal Junction Adenocarcinoma
China
Comparing the Diagnostic Sensitivity and Specificity of Pleural Fluid N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP) and Other Biochemical Gradient Criteria in Distinguishing Heart Failure and Non-heart Failure Related Pleural Effusions (CENTRE Study)Recruiting
NCT05797649N/AUpdated Nov 13, 2024
Sponsor: Chinese University of Hong Kong
Pleural Effusion · Heart Failure · Malignant Neoplasm · Fluid Overload
Hong Kong
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast CancerTerminated
NCT04060862Phase 1Updated Nov 8, 2024
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Australia, Brazil, Canada, Japan +3 more
Research Collaboration for a Precision Oncology Program (POP)Recruiting
NCT06680726N/AUpdated Nov 8, 2024
Sponsor: Andreas Wicki
Cancer
Switzerland
A Remote Evaluation of NAVIFY Oncology Hub Using Clinical SimulationCompleted
NCT05478135NAUpdated Nov 8, 2024
Sponsor: Prova Health Limited
Oncology
United Kingdom
Atezolizumab Combined With Chemotherapy in Extensive Stage SCLCCompleted
NCT04920981N/AUpdated Nov 7, 2024
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Small Cell Lung Cancer
France
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast CancerCompleted
NCT03726879Phase 3Updated Nov 5, 2024
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Brazil, Canada, Czechia, Germany +7 more
Optimization of Heart Failure (HF) Medical Therapy After Transcatheter Valve Intervention (TVI) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)Not Yet Recruiting
NCT06667128NAUpdated Nov 4, 2024
Sponsor: IRCCS Ospedale San Raffaele
Heart Failure · Valvulopathy · Aortic Stenosis · Aortic Regurgitation Disease
Italy
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected ParticipantsCompleted
NCT02952924Phase 1Updated Oct 31, 2024
Sponsor: Hoffmann-La Roche
Hepatitis B, Chronic
Australia, Bulgaria, China, Hong Kong, New Zealand +3 more
A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerCompleted
NCT03800836Phase 1Updated Oct 30, 2024
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Australia, France, Spain, United Kingdom
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal MelanomaCompleted
NCT04091217Phase 2Updated Oct 24, 2024
Sponsor: Hoffmann-La Roche
Melanoma
China
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III StudiesTerminated
NCT02118584Phase 3Updated Oct 23, 2024
Sponsor: Hoffmann-La Roche
Ulcerative Colitis
United States, Argentina, Australia, Austria, Belgium +37 more
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet ChemotherapyCompleted
NCT03191786Phase 3Updated Oct 23, 2024
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer
Argentina, Belgium, Brazil, Bulgaria, Canada +19 more
Polycystic Ovarian Syndrome (PCOS) Biomarker Evaluation StudyRecruiting
NCT06642831N/AUpdated Oct 15, 2024
Sponsor: University Hospital Erlangen
Polycystic Ovarian Syndrome (PCOS)
Germany
Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast CancerCompleted
NCT03164993Phase 2Updated Oct 15, 2024
Sponsor: Oslo University Hospital
Cancer, Breast · Triple Negative Breast Cancer
Denmark, Norway
Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid BiomarkersCompleted
NCT04750109N/AUpdated Oct 10, 2024
Sponsor: The Christie NHS Foundation Trust
Cancer of Unknown Primary Site
United Kingdom

Previous page Next page